# Premarket Notification 510(k) Summary

Assigned 510(k) Number: k071210 . Submitted by : Name: Contact Person:

Address:

Biomedical Diagnostics S.A (bmd)   
Christelle COURIVAUD   
Regulatory Affairs Manager   
Actipole 25, 4-6 Bld de Beaubourg   
77435 Marne-La-Vallée Cedex 2   
FRANCE   
33 (0)1 64 62 10 12   
33 (0)1 64 62 09 66   
Telephone:   
Fax:   
Establishment   
Registration Number:

US Agent correspondent:

Hoppe Regulatory Consultants   
Ms P. Ann HOPPE   
2335 Massey Lane   
Decatur GA 30033 USA   
Phone: 404 248 0002   
E-mail: Hoppe Regulatory@cs.com

# Device Name

Trade/Proprietary Name :

# FIDISTM CONNECTIVE $\mathbf { 1 0 ^ { * } }$ assay

Common/Usual Name :

MX006 - FIDISTM CONNECTIVE $\pmb { 1 0 ^ { \star } }$ : Detection test of 10 autoantibody specificities: double stranded DNA (dsDNA), SSA $6 0 \mathbf { k D a } ,$ , SSA 52kDa, SSB, Sm, Sm/RNP, Scl70, Jo-1, Ribosome and Centromere.

Classification Name:

Antinuclear antibody immunological test system

Trade/Proprietary Name : Classification Name:

FIDISTM Analyzer Instrumentation for Chemical Multiplex Systems

Trade/Proprietary Name : Classification Name:

CARISTM System Device, Microtiter diluting/Dispensing

# Intended use of the device

The FIDIS™ CONNECTIVE $\mathbf { 1 0 ^ { \star } }$ kit is a semi-quantitative homogeneous fluorescentbased microparticles immunoassay using flow cytometry. The test system is used to simultaneously detect the presence of 10 autoantibody specificities: double stranded DNA (dsDNA), SSA $6 0 ~ \mathrm { \ k D a }$ and $5 2 ~ \mathrm { \ k D a }$ ), SSB, Sm, Sm/RNP, Scl70, Jo1, ribosome and centromere.

(\*Antibodies to dsDNA, Sm, Sm/RNP, SSA, SB, Scl-70, Jo-1, ribosome and centromere can be reported using this assay).

# Clinical utility:

The results of the FIDIS™ CONNECTIVE $1 0 ^ { \star }$ are to be used in conjunction with the clinical findings and the other laboratory tests to aid in the diagnosis of connective diseases (systemic lupus erythematosus (SLE), Sjogren's syndrome, mixed connective tissue disease (MCTD), scleroderma, dermatomyositis and CREST syndrome).

FIDIS™ CONNECTIVE $\mathbf { 1 0 ^ { \star } }$ kit uses serum only, and is to be run on the FIDISTM Instrument and MLX-BOOSTER™M Software.

FIDIS™ CONNECTIVE $\mathbf { 1 0 ^ { \star } }$ kit may be used with the CARIS™ system (diluting and dispensing device).

This test is for in vitro diagnostic use.

# Materials supplied

<table><tr><td colspan="1" rowspan="1">1 x 96 wells microplate with filtering membrane and a lid.</td><td colspan="1" rowspan="1">1 plate</td></tr><tr><td colspan="1" rowspan="1">1 Vial (A) of 10 sets of color-coded microsphere beads coupled with dsDNA, SSA 60 kDa,SSA 52 kDa, SS-B, Sm, Sm/RNP. Scl-70. Jo-1, ribosomes, centromere antigen, plus 1 setof Internal standard beads.Lyophilized (to be diluted with the buffer named D)</td><td colspan="1" rowspan="1">Sufficient quantity toobtain 6mL afterreconstitution</td></tr><tr><td colspan="1" rowspan="1">1Vial (B) of sample dilution buffer (white vial)Ready to use</td><td colspan="1" rowspan="1">2 x 115mL</td></tr><tr><td colspan="1" rowspan="1">1 Vial of calibrator titered for the specificities to be mesuredReady to useEach titer is printed on the vial label</td><td colspan="1" rowspan="1">1 x 1,5mL</td></tr><tr><td colspan="1" rowspan="1">1 Vial of positive control concentrate. This control has a standard reactivity, that providesevidence of the proper functioning of reagents and correct assay performance.To be dilutedExpected values are printed on the vial label.</td><td colspan="1" rowspan="1">1 x 250 μL</td></tr><tr><td colspan="1" rowspan="1">1 Vial of negative control* concentrateTo be diluted</td><td colspan="1" rowspan="1">1 x 250μL</td></tr><tr><td colspan="1" rowspan="1">1 Viat of anti-human IgG coupled to phycoerythrinReady to use</td><td colspan="1" rowspan="1">1 x 12mL</td></tr><tr><td colspan="1" rowspan="1">1 Vial (C) of washing buffer (black vial)Ready to use</td><td colspan="1" rowspan="1">1 x 100mL</td></tr><tr><td colspan="1" rowspan="1">1 Vial (D) of reconstitution buffer for the microsphere setReady to use</td><td colspan="1" rowspan="1">1 x 6mL</td></tr><tr><td colspan="1" rowspan="1">Package insert</td><td colspan="1" rowspan="1">1</td></tr><tr><td colspan="1" rowspan="1">Microplate Assay Configuration Worksheet</td><td colspan="1" rowspan="1">1</td></tr><tr><td colspan="1" rowspan="1">Microplate sealing films</td><td colspan="1" rowspan="1">6</td></tr></table>

# Predicate Device

<table><tr><td rowspan=1 colspan=1>510K Number</td><td rowspan=1 colspan=1>Device Classification Name</td><td rowspan=1 colspan=1>Manufacturer Name</td></tr><tr><td rowspan=1 colspan=1>K053653</td><td rowspan=1 colspan=1>FIDISTM CONNECTIVE 10*</td><td rowspan=1 colspan=1>bmd</td></tr></table>

# Comparison with the predicate

Modited Devic FIDISTCONNECTIVE TO K05365. ISIMCONNECTIVE

<table><tr><td colspan="2" rowspan="1">Intended use</td><td colspan="1" rowspan="1">Individual determination in human serum ofIgG antibodies against:dsDNA, SSA 60kDa, SSA 52kDa, SSB,Sm, Sm/RNP, Scl70, Jo-1, Ribosome andCentromere</td><td colspan="1" rowspan="1">Same(minor text changes)</td></tr><tr><td colspan="1" rowspan="3">CO-E</td><td colspan="1" rowspan="1">Negative</td><td colspan="1" rowspan="3">&lt;30for the 10 specificities  - In IU/mL fordsDNA30-40- In AU/mL forfor the 10 specificitiesthe 9 other&gt;40           specificitiesfor the 10 specificities</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Equivocal</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Positive</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="2" rowspan="1">Material supplied</td><td colspan="1" rowspan="1">Microplate with caps</td><td colspan="1" rowspan="1">Microplate with sealing films</td></tr><tr><td colspan="2" rowspan="1">Beads</td><td colspan="1" rowspan="1">Vial of color-coded microsphere setready to use (6mL)</td><td colspan="1" rowspan="1">Vial of color-coded microsphere setLyophilized (sq 6mL)</td></tr><tr><td colspan="2" rowspan="1">Sample dilution</td><td colspan="1" rowspan="1">PBS-Tween concentrated</td><td colspan="1" rowspan="1">Sample dilution buffer ready to use</td></tr><tr><td colspan="2" rowspan="1">Washing buffer</td><td colspan="1" rowspan="1">PBS-Tween concentrated</td><td colspan="1" rowspan="1">Washing buffer ready to use</td></tr><tr><td colspan="2" rowspan="1">Internal standardbeads</td><td colspan="1" rowspan="1">No</td><td colspan="1" rowspan="1">Yes</td></tr><tr><td colspan="1" rowspan="3">Assay configuration</td><td colspan="1" rowspan="1">1 "reagent-blank" well1 "calibrator" well1 "negative control" well1 "positive control" well</td><td colspan="1" rowspan="1">1 "reagent-blank" well1 "negative control" well1 "positive control" well2 "calibrator" wells</td></tr><tr><td colspan="1" rowspan="1">Diluted sample wells</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">A second calibrator well every 48 wellseries</td><td colspan="1" rowspan="1">No</td></tr><tr><td colspan="1" rowspan="1">Incubation time</td><td colspan="1" rowspan="1">2 x 30mn RT</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Wash step</td><td colspan="1" rowspan="1">2 x 200μL</td><td colspan="1" rowspan="1">2 x 300μL</td></tr><tr><td colspan="1" rowspan="1">Assay protocol</td><td colspan="1" rowspan="1">Optional final wash step</td><td colspan="1" rowspan="1">Final wash step (not optional)</td></tr><tr><td colspan="1" rowspan="1">Software</td><td colspan="1" rowspan="1">Booster Version 1.35</td><td colspan="1" rowspan="1">Booster Version 2.2</td></tr><tr><td colspan="1" rowspan="1">Detection Method</td><td colspan="1" rowspan="1">Fluorescence(using Luminex 100)</td><td colspan="1" rowspan="1">Fluorescence(using Luminex 200)</td></tr><tr><td colspan="1" rowspan="1">Sample preparation</td><td colspan="1" rowspan="1">Manual preparation</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Automatic samplepreparation (option)</td><td colspan="1" rowspan="1">CARISTM</td><td colspan="1" rowspan="1">Same</td></tr></table>

# 7.Performance Characteristics

# 1. Analytical performance

# a.Precision

Precision of the assay was assessed in 53 samples. Precision was determined by calculating the within-run (intra-assay) and the between run (inter-assay).

For within run: 6 samples (except for Jol only 5 samples were tested) 10 times in a same run.

For between run: 6 samples (except for Jo1 only 5 samples were tested) in 6 runs, 3 times per run.

Table 1: Summary of FIDISTM CONNECTIVE 10\* precision results   

<table><tr><td rowspan=1 colspan=1>Sample range</td><td rowspan=1 colspan=1>Acceptancecriteria forwithin-runandbetween-run</td><td rowspan=1 colspan=1>Within-runminimal CV%for the 10parameters</td><td rowspan=1 colspan=1>Within-runmaximalCV% for the10 parameters</td><td rowspan=1 colspan=1>Between-runminimal CV%for the 10parameters</td><td rowspan=1 colspan=1>Between-runmaximalCV% for the10 parameters</td></tr><tr><td rowspan=1 colspan=1>Less than 10AU/mL or IU/mL</td><td rowspan=1 colspan=1>Notdetermined</td><td rowspan=1 colspan=1>5.9%</td><td rowspan=1 colspan=1>12.8%</td><td rowspan=1 colspan=1>7.4%</td><td rowspan=1 colspan=1>13.6%</td></tr><tr><td rowspan=1 colspan=1>10 to 29 AU/mLor IU/mL</td><td rowspan=1 colspan=1>CV≤20%</td><td rowspan=1 colspan=1>2.5%</td><td rowspan=1 colspan=1>11.8%</td><td rowspan=1 colspan=1>8.2%</td><td rowspan=1 colspan=1>17.3%</td></tr><tr><td rowspan=1 colspan=1>29 to 800 AU/mLor IU/mL</td><td rowspan=1 colspan=1>CV≤15%</td><td rowspan=1 colspan=1>2.1%</td><td rowspan=1 colspan=1>12.7%</td><td rowspan=1 colspan=1>4.5%</td><td rowspan=1 colspan=1>14.3%</td></tr></table>

# b. Linearity/ assay reportable range

FIDIS™M CONNECTIVE $1 0 ^ { * }$ assay has been optimized to express the average binding capacity at the current dilution (1/200) by a flow cytometric reading resulting of the median fluorescence value obtained from 200 microspheres per parameter.

Further dilutions potentially give rise to inaccurate results because the reaction conditions and the equilibrium of the immunological reaction would be modified.

# c. Interfering Substances

The study was conducted by testing 30 negative samples (for dsDNA, SSA 60kDa, SSA 52kDa, SSB, Sm, Sm/RNP, Scl70, Jo-1, Ribosome and Centromere) characterized as positive for various potential interferences obtained from routine laboratory (listed in following table).

Table 2: Potential interferences results   

<table><tr><td rowspan=2 colspan=1></td><td rowspan=1 colspan=9>Number of positive sample</td></tr><tr><td rowspan=1 colspan=1>dsDNA</td><td rowspan=1 colspan=1>SSA60 KD</td><td rowspan=1 colspan=1>SSA52kD</td><td rowspan=1 colspan=1>SSB</td><td rowspan=1 colspan=1>Sm</td><td rowspan=1 colspan=1>Sm/RNP</td><td rowspan=1 colspan=1>Scl70</td><td rowspan=1 colspan=1>Jol</td><td rowspan=1 colspan=1>Ribo</td></tr><tr><td rowspan=1 colspan=1>Cryoglobulinemia N*=2</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>Complement N*=7</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>IgG monoclonalimmunoglobulins N*=1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>IgM monoclonalimmunoglobulins N*=5</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>Rheumatoid factor N*=8</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>Plasma N*=3</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>Hemolyzed sera N*=3</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>Anti-smooth muscleantibodies N*=1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td></tr></table>

$\ast _ { \mathrm { N } } .$ number of samples tested

Threshold values were estimated from the 2 selected populations:

50 samples from blood donors 48 samples selected for their potential biological interferences   
The negative thresholds (30AU/mL or $3 0 \mathrm { I U / m L } ,$ correspond to the $9 7 . 9 \%$ for   
dsDNA, SSA, Sm/RNP; $9 9 . 0 \%$ for centromere and ribosome, and $100 \%$ for   
SSB, Sm, Scl70 and Jo1 for the populations studied.

e. Stability of the assay results after final wash step

This assay included 3 test series with:

5 positive samples for SSA 52kDa, SSA 60kDa, SSB, Sm, Sm/RNP, Scl70, dsDNA and Centromere;   
4 positive samples for Jol;   
3 positive samples for Ribosome.

Each series of tests was washed and read after different times:

${ \bf T } { \bf \bf \bf \equiv } { \bf 0 }$ hour: the first series of tests was read immediately after the final wash step.   
EY $\Upsilon { = } 4$ hours: the second series of test was read after 4 hours of storage at room temperature away from direct sunlight.   
$\mathrm { T } { = } 1 8$ hours: the last series was read after 18 hours of storage at room temperature away from direct sunlight.

![](images/5eecb086d402ace142d10a365c079c229ec9845dde861dce13e776ded2912acb.jpg)

<table><tr><td colspan="1" rowspan="10">%CV ≤15%</td><td colspan="1" rowspan="5">SSA 52</td><td colspan="1" rowspan="1">Sample 1</td><td colspan="1" rowspan="1">169</td><td colspan="1" rowspan="1">9</td><td colspan="1" rowspan="5">Notcalculated</td><td colspan="1" rowspan="5">Notcalculated</td></tr><tr><td colspan="1" rowspan="1">Sample 2</td><td colspan="1" rowspan="1">85</td><td colspan="1" rowspan="1">5</td></tr><tr><td colspan="1" rowspan="1">Sample 3</td><td colspan="1" rowspan="1">52</td><td colspan="1" rowspan="1">5</td></tr><tr><td colspan="1" rowspan="1">Sample 4</td><td colspan="1" rowspan="1">130</td><td colspan="1" rowspan="1">5</td></tr><tr><td colspan="1" rowspan="1">Sample 5</td><td colspan="1" rowspan="1">180</td><td colspan="1" rowspan="1">11</td></tr><tr><td colspan="1" rowspan="5">SSA 60</td><td colspan="1" rowspan="1">Sample 6</td><td colspan="1" rowspan="1">49</td><td colspan="1" rowspan="1">7</td><td colspan="1" rowspan="5">Notcalculated</td><td colspan="1" rowspan="5">Notcalculated</td></tr><tr><td colspan="1" rowspan="1">Sample 7</td><td colspan="1" rowspan="1">94</td><td colspan="1" rowspan="1">11</td></tr><tr><td colspan="1" rowspan="1">Sample 8</td><td colspan="1" rowspan="1">68</td><td colspan="1" rowspan="1">4</td></tr><tr><td colspan="1" rowspan="1">Sample 9</td><td colspan="1" rowspan="1">85</td><td colspan="1" rowspan="1">7</td></tr><tr><td colspan="1" rowspan="1">Sample 10</td><td colspan="1" rowspan="1">95</td><td colspan="1" rowspan="1">13</td></tr><tr><td colspan="1" rowspan="37">%CV ≤15%</td><td colspan="1" rowspan="5">SSB</td><td colspan="1" rowspan="1">Sample 11</td><td colspan="1" rowspan="1">167</td><td colspan="1" rowspan="1">6</td><td colspan="1" rowspan="5">Notcalculated</td><td colspan="1" rowspan="5">Notcalculated</td></tr><tr><td colspan="1" rowspan="1">Sample 12</td><td colspan="1" rowspan="1">59</td><td colspan="1" rowspan="1">5</td></tr><tr><td colspan="1" rowspan="1">Sample 13</td><td colspan="1" rowspan="1">85</td><td colspan="1" rowspan="1">7</td></tr><tr><td colspan="1" rowspan="1">Sample 14</td><td colspan="1" rowspan="1">121</td><td colspan="1" rowspan="1">11</td></tr><tr><td colspan="1" rowspan="1">Sample 15</td><td colspan="1" rowspan="1">23</td><td colspan="1" rowspan="1">5</td></tr><tr><td colspan="1" rowspan="5">Sm</td><td colspan="1" rowspan="1">Sample 16</td><td colspan="1" rowspan="1">33</td><td colspan="1" rowspan="1">7</td><td colspan="1" rowspan="5">Notcalculated</td><td colspan="1" rowspan="5">Notcalculated</td></tr><tr><td colspan="1" rowspan="1">Sample 17</td><td colspan="1" rowspan="1">309</td><td colspan="1" rowspan="1">10</td></tr><tr><td colspan="1" rowspan="1">Sample 18</td><td colspan="1" rowspan="1">50</td><td colspan="1" rowspan="1">7</td></tr><tr><td colspan="1" rowspan="1">Sample 19</td><td colspan="1" rowspan="1">103</td><td colspan="1" rowspan="1">13</td></tr><tr><td colspan="1" rowspan="1">Sample 20</td><td colspan="1" rowspan="1">147</td><td colspan="1" rowspan="1">3</td></tr><tr><td colspan="1" rowspan="5">Sm/RNP</td><td colspan="1" rowspan="1">Sample 21</td><td colspan="1" rowspan="1">202</td><td colspan="1" rowspan="1">7</td><td colspan="1" rowspan="5">Notcalculated</td><td colspan="1" rowspan="5">Notcalculated</td></tr><tr><td colspan="1" rowspan="1">Sample 22</td><td colspan="1" rowspan="1">82</td><td colspan="1" rowspan="1">11</td></tr><tr><td colspan="1" rowspan="1">Sample 23</td><td colspan="1" rowspan="1">374</td><td colspan="1" rowspan="1">11</td></tr><tr><td colspan="1" rowspan="1">Sample 24</td><td colspan="1" rowspan="1">59</td><td colspan="1" rowspan="1">9</td></tr><tr><td colspan="1" rowspan="1">Sample 25</td><td colspan="1" rowspan="1">116</td><td colspan="1" rowspan="1">13</td></tr><tr><td colspan="1" rowspan="5">Scl70</td><td colspan="1" rowspan="1">Sample 26</td><td colspan="1" rowspan="1">57</td><td colspan="1" rowspan="1">4</td><td colspan="1" rowspan="5">Notcalculated</td><td colspan="1" rowspan="5">Notcalculated</td></tr><tr><td colspan="1" rowspan="1">Sample 27</td><td colspan="1" rowspan="1">55</td><td colspan="1" rowspan="1">5</td></tr><tr><td colspan="1" rowspan="1">Sample 28</td><td colspan="1" rowspan="1">144</td><td colspan="1" rowspan="1">3</td></tr><tr><td colspan="1" rowspan="1">Sample 29</td><td colspan="1" rowspan="1">308</td><td colspan="1" rowspan="1">4</td></tr><tr><td colspan="1" rowspan="1">Sample 30</td><td colspan="1" rowspan="1">188</td><td colspan="1" rowspan="1">7</td></tr><tr><td colspan="1" rowspan="4">Jo1</td><td colspan="1" rowspan="1">Sample 31</td><td colspan="1" rowspan="1">79</td><td colspan="1" rowspan="1">13</td><td colspan="1" rowspan="4">Notcalculated</td><td colspan="1" rowspan="4">Notcalculated</td></tr><tr><td colspan="1" rowspan="1">Sample 32</td><td colspan="1" rowspan="1">242</td><td colspan="1" rowspan="1">6</td></tr><tr><td colspan="1" rowspan="1">Sample 33</td><td colspan="1" rowspan="1">59</td><td colspan="1" rowspan="1">7</td></tr><tr><td colspan="1" rowspan="1">Sample 34</td><td colspan="1" rowspan="1">77</td><td colspan="1" rowspan="1">6</td></tr><tr><td colspan="1" rowspan="5">Centromere</td><td colspan="1" rowspan="1">Sample 35</td><td colspan="1" rowspan="1">91</td><td colspan="1" rowspan="1">16</td><td colspan="1" rowspan="1">81</td><td colspan="1" rowspan="1">7</td></tr><tr><td colspan="1" rowspan="1">Sample 36</td><td colspan="1" rowspan="1">82</td><td colspan="1" rowspan="1">11</td><td colspan="1" rowspan="1">78</td><td colspan="1" rowspan="1">11</td></tr><tr><td colspan="1" rowspan="1">Sample 37</td><td colspan="1" rowspan="1">81</td><td colspan="1" rowspan="1">7</td><td colspan="1" rowspan="1">78</td><td colspan="1" rowspan="1">6</td></tr><tr><td colspan="1" rowspan="1">Sample 38</td><td colspan="1" rowspan="1">22</td><td colspan="1" rowspan="1">9</td><td colspan="1" rowspan="1">21</td><td colspan="1" rowspan="1">5</td></tr><tr><td colspan="1" rowspan="1">Sample 39</td><td colspan="1" rowspan="1">19</td><td colspan="1" rowspan="1">5</td><td colspan="1" rowspan="1">20</td><td colspan="1" rowspan="1">0</td></tr><tr><td colspan="1" rowspan="3">Ribosome</td><td colspan="1" rowspan="1">Sample 40</td><td colspan="1" rowspan="1">40</td><td colspan="1" rowspan="1">13</td><td colspan="1" rowspan="3">Notcalculated</td><td colspan="1" rowspan="3">Notcalculated</td></tr><tr><td colspan="1" rowspan="1">Sample 41</td><td colspan="1" rowspan="1">141</td><td colspan="1" rowspan="1">7</td></tr><tr><td colspan="1" rowspan="1">Sample 42</td><td colspan="1" rowspan="1">71</td><td colspan="1" rowspan="1">6</td></tr><tr><td colspan="1" rowspan="5">dsDNA</td><td colspan="1" rowspan="1">Sample 43</td><td colspan="1" rowspan="1">49</td><td colspan="1" rowspan="1">11</td><td colspan="1" rowspan="5">Notcalculated</td><td colspan="1" rowspan="5">Notcalculated</td></tr><tr><td colspan="1" rowspan="1">Sample 44</td><td colspan="1" rowspan="1">123</td><td colspan="1" rowspan="1">9</td></tr><tr><td colspan="1" rowspan="1">Sample 45</td><td colspan="1" rowspan="1">51</td><td colspan="1" rowspan="1">10</td></tr><tr><td colspan="1" rowspan="1">Sample 46</td><td colspan="1" rowspan="1">184</td><td colspan="1" rowspan="1">3</td></tr><tr><td colspan="1" rowspan="1">Sample 47</td><td colspan="1" rowspan="1">62</td><td colspan="1" rowspan="1">8</td></tr></table>

Based on the common laboratories practices, the time range recommended is "one hour for a plate when stored at room temperature away from direct sunlight".

# 2. Comparison study with predicate

bmd has compared the results obtained with modified FIDISTM CONNECTIVE $\mathbf { 1 0 ^ { * } }$ versus the results obtained with predicate FIDISTM CONNECTIVE $\mathbf { 1 0 ^ { * } }$ K053653 in manual use.

The study was performed on 264 samples characterized with the predicate test and the result repartition is described as below:

194 samples were positive for one or more parameters (see table 5).

70 negative samples including some samples evaluated for their potential biological interferences.

Table 5: Number of positive samples per parameter.   

<table><tr><td rowspan=1 colspan=1>57</td></tr><tr><td rowspan=1 colspan=1>48</td></tr><tr><td rowspan=1 colspan=1>23</td></tr><tr><td rowspan=1 colspan=1>29</td></tr><tr><td rowspan=1 colspan=1>40</td></tr><tr><td rowspan=1 colspan=1>28</td></tr><tr><td rowspan=1 colspan=1>26</td></tr><tr><td rowspan=1 colspan=1>26</td></tr><tr><td rowspan=1 colspan=1>17</td></tr><tr><td rowspan=1 colspan=1>46</td></tr></table>

All equivocal samples with predicate and modified FIDIS™ CONNECTIVE $\mathbf { 1 0 ^ { * } }$ assays are considered negative for the comparison and the evaluation studies.

Tables 6: Specificity performances   

<table><tr><td rowspan=2 colspan=1>dsDNAN=116</td><td rowspan=2 colspan=1></td><td rowspan=1 colspan=3></td></tr><tr><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=3 colspan=1></td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>45</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>46</td></tr><tr><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>66</td><td rowspan=1 colspan=1>70</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>49</td><td rowspan=1 colspan=1>67</td><td rowspan=1 colspan=1>116</td></tr></table>

<table><tr><td rowspan=2 colspan=2>SSA 60kDaN=118</td><td rowspan=1 colspan=3></td></tr><tr><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=3 colspan=1></td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>48</td><td rowspan=1 colspan=1>I</td><td rowspan=1 colspan=1>49</td></tr><tr><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>69</td><td rowspan=1 colspan=1>69</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>48</td><td rowspan=1 colspan=1>70</td><td rowspan=1 colspan=1>118</td></tr></table>

There were 3 equivocal results with the assay. For purposes of calculation, these results were considered as negative. Positive percent agreement: $9 1 . 8 4 \%$ (45/49) Negative percent agreement: $9 8 . 5 1 \%$ (66/67) Overall agreement: $9 5 . 6 9 \%$ (111/116)

There were 2 equivocal results with the assay. For purposes of calculation, these results were considered as negative. Positive percent agreement: $100 \%$ (48/48) Negative percent agreement: $9 8 . 5 7 \%$ (69/70) Overall agreement: $9 9 . 1 5 \%$ (117/118)

<table><tr><td rowspan=2 colspan=2>SSA 52kDaN=127</td><td rowspan=1 colspan=3></td></tr><tr><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=3 colspan=1></td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>58</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>60</td></tr><tr><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>64</td><td rowspan=1 colspan=1>67</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>61</td><td rowspan=1 colspan=1>66</td><td rowspan=1 colspan=1>127</td></tr></table>

<table><tr><td rowspan=2 colspan=2>SS-BN=93</td><td rowspan=1 colspan=3></td></tr><tr><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=3 colspan=1></td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>23</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>25</td></tr><tr><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>68</td><td rowspan=1 colspan=1>68</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>23</td><td rowspan=1 colspan=1>70</td><td rowspan=1 colspan=1>93</td></tr></table>

There were 3 equivocal results with the assay. For purposes of calculation, these results were considered as negative.

Positive percent agreement: $9 5 . 0 8 \%$ (58/61) Negative percent agreement: $9 6 . 9 7 \%$ (64/66) Overall agreement: $9 6 . 0 6 \%$ (122/127)

There were I equivocal result with the assay. For purposes of calculation, these results were considered as negative.

Positive percent agreement: $100 \%$ (23/23) Negative percent agreement: $9 7 . 1 4 \%$ (68/70) Overall agreement: $9 7 . 8 5 \%$ (91/93)

<table><tr><td rowspan=2 colspan=2>SmN=99</td><td rowspan=1 colspan=3></td></tr><tr><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=3 colspan=1></td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>23</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>25</td></tr><tr><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>73</td><td rowspan=1 colspan=1>74</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>24</td><td rowspan=1 colspan=1>75</td><td rowspan=1 colspan=1>99</td></tr></table>

<table><tr><td rowspan=2 colspan=2>Sm/RNPN= 110</td><td rowspan=1 colspan=3></td></tr><tr><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=3 colspan=1></td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>31</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>33</td></tr><tr><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>76</td><td rowspan=1 colspan=1>77</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>32</td><td rowspan=1 colspan=1>78</td><td rowspan=1 colspan=1>110</td></tr></table>

There were 6 equivocal results with the assay. For purposes of calculation, these results were considered as negative.

Positive percent agreement: $9 5 . 8 3 \%$ (23/24) Negative percent agreement: $9 7 . 3 3 \%$ (73175) Overall agreement: $9 6 . 9 7 \%$ (96/99)

There were 7 equivocal results with the assay. For purposes of calculation, these results were considered as negative.

Positive percent agreement: $9 6 . 8 8 \%$ (31/32) Negative percent agreement: $9 7 . 4 4 \%$ (76/78) Overall agreement: $9 7 . 2 7 \%$ (107/110)

<table><tr><td rowspan=2 colspan=2>Scl70N=98</td><td rowspan=1 colspan=3>HOAT</td></tr><tr><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=3 colspan=1></td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>27</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>29</td></tr><tr><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>68</td><td rowspan=1 colspan=1>69</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>28</td><td rowspan=1 colspan=1>70</td><td rowspan=1 colspan=1>98</td></tr></table>

<table><tr><td rowspan=2 colspan=2>Jo1N=96</td><td rowspan=1 colspan=3></td></tr><tr><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=3 colspan=1></td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>26</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>26</td></tr><tr><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>69</td><td rowspan=1 colspan=1>70</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>27</td><td rowspan=1 colspan=1>69</td><td rowspan=1 colspan=1>96</td></tr></table>

There is 1 equivocal result with the assay. For purposes of calculation, these results were considered as negative.

Positive percent agreement: $9 6 . 4 3 \%$ (27/28) Negative percent agreement: $9 7 . 1 4 \%$ (68/70) Overall agreement: $9 6 . 9 4 \%$ (95/98)

There is 0 equivocal result with the assay.

Positive percent agreement: $9 6 . 3 0 \%$ (26/27) Negative percent agreement: $100 \%$ (69/69) Overall agreement: $9 8 . 9 6 \%$ (95/96)

There were 7 equivocal results with the assay. For purposes of calculation, these results were considered as negative.

Positive percent agreement: $8 3 . 3 3 \%$ (20/24) Negative percent agreement: $100 \%$ (72/72) Overall agreement: $9 5 . 8 3 \%$ (92/96)

Table 7: Summary of performance agreement results   

<table><tr><td rowspan=2 colspan=2>CentromereN=96</td><td rowspan=1 colspan=3></td></tr><tr><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=3 colspan=1></td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>20</td></tr><tr><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>72</td><td rowspan=1 colspan=1>76</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>24</td><td rowspan=1 colspan=1>72</td><td rowspan=1 colspan=1>96</td></tr></table>

<table><tr><td rowspan=2 colspan=2>RibosomeN=87</td><td rowspan=1 colspan=3></td></tr><tr><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=3 colspan=1></td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>18</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>18</td></tr><tr><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>69</td><td rowspan=1 colspan=1>69</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>18</td><td rowspan=1 colspan=1>69</td><td rowspan=1 colspan=1>87</td></tr></table>

There is 1 equivocal result with the assay. For purposes of calculation, these results were considered as negative. Positive percent agreement: $100 \%$ (18/18) Negative percent agreement: $100 \%$ (69/69) Overall agreement: $100 \%$ (87/87)

![](images/86d6b5f9750e61d780082a7c3496c181004e8ed1fe35f2d97ac59c4839d4d6bf.jpg)

<table><tr><td rowspan=1 colspan=1>dsDNA</td><td rowspan=1 colspan=1>116</td><td rowspan=1 colspan=1>91.84%</td><td rowspan=1 colspan=1>98.51%</td><td rowspan=1 colspan=1>95.69%</td></tr><tr><td rowspan=1 colspan=1>SSA 60 kDa</td><td rowspan=1 colspan=1>118</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>98.57%</td><td rowspan=1 colspan=1>99.15%</td></tr><tr><td rowspan=1 colspan=1>SSA 52 kDa</td><td rowspan=1 colspan=1>127</td><td rowspan=1 colspan=1>95.08%</td><td rowspan=1 colspan=1>96.97%</td><td rowspan=1 colspan=1>96.06%</td></tr><tr><td rowspan=1 colspan=1>SSB</td><td rowspan=1 colspan=1>93</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>97.14%</td><td rowspan=1 colspan=1>97.85%</td></tr><tr><td rowspan=1 colspan=1>Sm</td><td rowspan=1 colspan=1>99</td><td rowspan=1 colspan=1>95.83%</td><td rowspan=1 colspan=1>97.33%</td><td rowspan=1 colspan=1>96.97%</td></tr><tr><td rowspan=1 colspan=1>Sm/RNP</td><td rowspan=1 colspan=1>110</td><td rowspan=1 colspan=1>96.88%</td><td rowspan=1 colspan=1>97.44%</td><td rowspan=1 colspan=1>97.27%</td></tr><tr><td rowspan=1 colspan=1>Scl70</td><td rowspan=1 colspan=1>98</td><td rowspan=1 colspan=1>96.43%</td><td rowspan=1 colspan=1>97.14%</td><td rowspan=1 colspan=1>96.94%</td></tr><tr><td rowspan=1 colspan=1>Jo1</td><td rowspan=1 colspan=1>96</td><td rowspan=1 colspan=1>96.3%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>98.96%</td></tr><tr><td rowspan=1 colspan=1>Centromere</td><td rowspan=1 colspan=1>96</td><td rowspan=1 colspan=1>83.33%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>95.83%</td></tr><tr><td rowspan=1 colspan=1>Ribosome</td><td rowspan=1 colspan=1>87</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>100%</td></tr></table>

In addition to the analysis above, the $9 5 \%$ one-sided lower confidence limit in percent of proportion agreement( $9 5 \%$ LCL $( \% )$ was calculated using the Exact Binomial Test for proportions to determine how low this proportion could be with a $9 5 \%$ confidence.

Table 8: Summary of agreements results - 95% LCL (%)   

<table><tr><td rowspan=1 colspan=1>AntigenicSpecificity</td><td rowspan=1 colspan=4>Positive percent agreement</td><td rowspan=1 colspan=4>Negative percent agreement</td><td rowspan=1 colspan=4>Overall percent agreement</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>R</td><td rowspan=1 colspan=1>P1(%)</td><td rowspan=1 colspan=1>95%LCL (%)</td><td rowspan=1 colspan=1>N2</td><td rowspan=1 colspan=1>R2</td><td rowspan=1 colspan=1>P2(%)</td><td rowspan=1 colspan=1>95%LCL (%)</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>R</td><td rowspan=1 colspan=1>P(%)</td><td rowspan=1 colspan=1>95%LCL (%)</td></tr><tr><td rowspan=1 colspan=1>dsDNA</td><td rowspan=1 colspan=1>49</td><td rowspan=1 colspan=1>45</td><td rowspan=1 colspan=1>91.84</td><td rowspan=1 colspan=1>82.29</td><td rowspan=1 colspan=1>67</td><td rowspan=1 colspan=1>66</td><td rowspan=1 colspan=1>98.51</td><td rowspan=1 colspan=1>93.11</td><td rowspan=1 colspan=1>116</td><td rowspan=1 colspan=1>111</td><td rowspan=1 colspan=1>95.69</td><td rowspan=1 colspan=1>91.15</td></tr><tr><td rowspan=1 colspan=1>SSA 60 kDa</td><td rowspan=1 colspan=1>48</td><td rowspan=1 colspan=1>48</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>93.95</td><td rowspan=1 colspan=1>70</td><td rowspan=1 colspan=1>69</td><td rowspan=1 colspan=1>98.57</td><td rowspan=1 colspan=1>93.40</td><td rowspan=1 colspan=1>118</td><td rowspan=1 colspan=1>117</td><td rowspan=1 colspan=1>99.15</td><td rowspan=1 colspan=1>96.04</td></tr><tr><td rowspan=1 colspan=1>SSA 52 kDa</td><td rowspan=1 colspan=1>61</td><td rowspan=1 colspan=1>58</td><td rowspan=1 colspan=1>95.08</td><td rowspan=1 colspan=1>87.78</td><td rowspan=1 colspan=1>665</td><td rowspan=1 colspan=1>64</td><td rowspan=1 colspan=1>96.97</td><td rowspan=1 colspan=1>90.77</td><td rowspan=1 colspan=1>127</td><td rowspan=1 colspan=1>122</td><td rowspan=1 colspan=1>96.06</td><td rowspan=1 colspan=1>91.90</td></tr><tr><td rowspan=1 colspan=1>SSB</td><td rowspan=1 colspan=1>23</td><td rowspan=1 colspan=1>23</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>87.79</td><td rowspan=1 colspan=1>70</td><td rowspan=1 colspan=1>68</td><td rowspan=1 colspan=1>97.14</td><td rowspan=1 colspan=1>91.28</td><td rowspan=1 colspan=1>93</td><td rowspan=1 colspan=1>91</td><td rowspan=1 colspan=1>97.85</td><td rowspan=1 colspan=1>93.39</td></tr><tr><td rowspan=1 colspan=1>Sm</td><td rowspan=1 colspan=1>24</td><td rowspan=1 colspan=1>23</td><td rowspan=1 colspan=1>95.83</td><td rowspan=1 colspan=1>81.71</td><td rowspan=1 colspan=1>7.5</td><td rowspan=1 colspan=1>73</td><td rowspan=1 colspan=1>97.33</td><td rowspan=1 colspan=1>91.84</td><td rowspan=1 colspan=1>999</td><td rowspan=1 colspan=1>96</td><td rowspan=1 colspan=1>96.97</td><td rowspan=1 colspan=1>92.35</td></tr><tr><td rowspan=1 colspan=1>Sm/RNP</td><td rowspan=1 colspan=1>32</td><td rowspan=1 colspan=1>31</td><td rowspan=1 colspan=1>96.88</td><td rowspan=1 colspan=1>86.02</td><td rowspan=1 colspan=1>78</td><td rowspan=1 colspan=1>76</td><td rowspan=1 colspan=1>97.44</td><td rowspan=1 colspan=1>92.15</td><td rowspan=1 colspan=1>110</td><td rowspan=1 colspan=1>107</td><td rowspan=1 colspan=1>97.27</td><td rowspan=1 colspan=1>93.10</td></tr><tr><td rowspan=1 colspan=1>Scl70</td><td rowspan=1 colspan=1>28</td><td rowspan=1 colspan=1>27</td><td rowspan=1 colspan=1>96.43</td><td rowspan=1 colspan=1>84.15</td><td rowspan=1 colspan=1>70</td><td rowspan=1 colspan=1>68</td><td rowspan=1 colspan=1>97.14</td><td rowspan=1 colspan=1>91.28</td><td rowspan=1 colspan=1>98</td><td rowspan=1 colspan=1>95</td><td rowspan=1 colspan=1>96.94</td><td rowspan=1 colspan=1>92.28</td></tr><tr><td rowspan=1 colspan=1>Jo1</td><td rowspan=1 colspan=1>27</td><td rowspan=1 colspan=1>26</td><td rowspan=1 colspan=1>96.3</td><td rowspan=1 colspan=1>83.60</td><td rowspan=1 colspan=1>69</td><td rowspan=1 colspan=1>69</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>95.75</td><td rowspan=1 colspan=1>96</td><td rowspan=1 colspan=1>95</td><td rowspan=1 colspan=1>98.96</td><td rowspan=1 colspan=1>95.15</td></tr><tr><td rowspan=1 colspan=1>Centromere</td><td rowspan=1 colspan=1>24</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>83.33</td><td rowspan=1 colspan=1>65.82</td><td rowspan=1 colspan=1>7.2</td><td rowspan=1 colspan=1>72</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>95.92</td><td rowspan=1 colspan=1>96</td><td rowspan=1 colspan=1>92</td><td rowspan=1 colspan=1>95.83</td><td rowspan=1 colspan=1>90.72</td></tr><tr><td rowspan=1 colspan=1>Ribosome</td><td rowspan=1 colspan=1>18</td><td rowspan=1 colspan=1>18</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>84.67</td><td rowspan=1 colspan=1>69</td><td rowspan=1 colspan=1>69</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>95.75</td><td rowspan=1 colspan=1>87</td><td rowspan=1 colspan=1>87</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>96.62</td></tr></table>

EY $\mathbf { N } _ { 1 } = \mathbf { N } \mathbf { 0 }$ of positives; ${ \bf R } _ { 1 } = { \bf N } _ { 0 }$ of positive agreements; ${ \bf P } _ { 1 } = { \bf R } _ { 1 } / { \bf N } _ { 1 }$ EY ${ \bf N } _ { 2 } = { \bf N } _ { \bf 0 }$ of negatives; ${ \bf R } _ { 2 } = { \bf N } { \bf o } .$ of negative agreements; ${ \bf P } _ { 2 } = { \bf R } _ { 2 } / { \bf N } _ { 2 }$ $\mathbf { N } = \mathbf { N } _ { 1 } + \mathbf { N } _ { 2 }$ , ${ \bf R } = { \bf R } _ { 1 } + { \bf R } _ { 2 }$ ${ \bf P } = { \bf R } / { \bf N }$

All of results show that $\mathbf { F I D 1 S } ^ { \mathrm { T M } }$ CONNECTIVE $\mathbf { 1 0 ^ { * } }$ system can be considered IV $\mathbf { 1 0 ^ { * } }$ system.

# 3. Comparison study with predicate

a. Precision

Precision of the assay was assessed in 36 samples. Precision was determined by calculating the within-run (intra-assay) and the between run (inter-assay):

For within run: 4 samples 10 times in a same run. For between run: 4 samples in 6 runs, 3 times per run.

Table 9: Summary of CARISTM Precision results   

<table><tr><td rowspan=1 colspan=1>Sample range</td><td rowspan=1 colspan=1>Acceptancecriteria forwithin-runandbetween-run</td><td rowspan=1 colspan=1>Within-runminimal CV%for the 10parameters</td><td rowspan=1 colspan=1>Within-runmaximalCV% for the10 parameters</td><td rowspan=1 colspan=1>Between-runminimal CV%for the 10parameters</td><td rowspan=1 colspan=1>Between-runmaximalCV% for the10 parameters</td></tr><tr><td rowspan=1 colspan=1>Less than 10AU/mL or IU/mL</td><td rowspan=1 colspan=1>Notdetermined</td><td rowspan=1 colspan=1>Not evaluated</td><td rowspan=1 colspan=1>Not evaluated</td><td rowspan=1 colspan=1>Not evaluated</td><td rowspan=1 colspan=1>Not evaluated</td></tr><tr><td rowspan=1 colspan=1>10 to 29 AU/mLor IU/mL</td><td rowspan=1 colspan=1>CV≤20%</td><td rowspan=1 colspan=1>3.8%</td><td rowspan=1 colspan=1>10.3%</td><td rowspan=1 colspan=1>7.3%</td><td rowspan=1 colspan=1>13.9%</td></tr><tr><td rowspan=1 colspan=1>29 to 800 AU/mLor IU/mL</td><td rowspan=1 colspan=1>CV≤15%</td><td rowspan=1 colspan=1>1.7%</td><td rowspan=1 colspan=1>10.8%</td><td rowspan=1 colspan=1>3.7%</td><td rowspan=1 colspan=1>12.5%</td></tr></table>

# b. Comparison study (manual versus automated assay preparation steps)

bmd has compared the results obtained with the modified FIDISTM CONNECTIVE $\mathbf { 1 0 ^ { * } }$ for the manual or automated (with CARISTM) assay preparation steps.

The study was performed on 264 samples characterized with the predicate test and the result repartition is described as below:

194 samples were positive for one or more parameters (see Table 12) 70 negative samples including some samples evaluated for their potential biological interferences.

![](images/d65e3d5c895c2af2f5b2f8bd2ae56eb966e5f172aa154d15617042e3926c77ac.jpg)

All equivocal samples with FIDIS™ CONNECTIVE $\mathbf { 1 0 ^ { * } }$ assays are considered negative for the comparison and the evaluation studies.

Table 10: Number of the pathological population per parameter.   
Tables 11: Agreement performances   

<table><tr><td rowspan=2 colspan=2>dsDNAN=112</td><td rowspan=1 colspan=3></td></tr><tr><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=3 colspan=1></td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>43</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>43</td></tr><tr><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>69</td><td rowspan=1 colspan=1>69</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>43</td><td rowspan=1 colspan=1>69</td><td rowspan=1 colspan=1>112</td></tr></table>

There were 4 equivocal results with the assay. For purposes of calculation, these results were considered as negative. Positive percent agreement: $100 \%$ (43/43) Negative percent agreement: $100 \%$ (69/69) Overall agreement: $1 0 0 \%$ (112/112)

<table><tr><td rowspan=2 colspan=2>SSA 60kDaN=110</td><td rowspan=1 colspan=3></td></tr><tr><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=3 colspan=1></td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>42</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>42</td></tr><tr><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>68</td><td rowspan=1 colspan=1>68</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>42</td><td rowspan=1 colspan=1>68</td><td rowspan=1 colspan=1>110</td></tr></table>

There were I equivocal results with the assay. For purposes of calculation, these results were considered as negative. Positive percent agreement: $1 0 0 \%$ (42/42) Negative percent agreement: $100 \%$ (68/68) Overall agreement: $1 0 0 \%$ (110/110)

Tables 11: Agreement performances   

<table><tr><td rowspan=2 colspan=1>dsDNAN=112</td><td rowspan=2 colspan=1></td><td rowspan=1 colspan=3></td></tr><tr><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=3 colspan=1></td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>43</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>43</td></tr><tr><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>69</td><td rowspan=1 colspan=1>69</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>43</td><td rowspan=1 colspan=1>69</td><td rowspan=1 colspan=1>112</td></tr></table>

<table><tr><td rowspan=2 colspan=2>SSA 60kDaN=110</td><td rowspan=1 colspan=3>MANUAL</td></tr><tr><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=3 colspan=1></td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>42</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>42</td></tr><tr><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>68</td><td rowspan=1 colspan=1>68</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>42</td><td rowspan=1 colspan=1>68</td><td rowspan=1 colspan=1>110</td></tr></table>

There were 4 equivocal results with the assay. For purposes of calculation, these results were considered as negative.

Positive percent agreement: $100 \%$ (43/43) Negative percent agrecment: $100 \%$ (69/69) Overall agrecment: $100 \%$ (112/112)

There were I equivocal results with the assay. For purposes of calculation, these results were considered as negative. Positive percent agrecment: $100 \%$ (42/42) Negative percent agreement: $100 \%$ (68/68) Overall agreement: $100 \%$ (110/110)

<table><tr><td rowspan=2 colspan=2>SSA 52kDaN=118</td><td rowspan=1 colspan=3></td></tr><tr><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=3 colspan=1></td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>52</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>53</td></tr><tr><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>65</td><td rowspan=1 colspan=1>65</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>52</td><td rowspan=1 colspan=1>66</td><td rowspan=1 colspan=1>118</td></tr></table>

<table><tr><td rowspan=2 colspan=2>SSBN=92</td><td rowspan=1 colspan=3>MANUAL</td></tr><tr><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=3 colspan=1></td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>25</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>25</td></tr><tr><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>67</td><td rowspan=1 colspan=1>67</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>25</td><td rowspan=1 colspan=1>67</td><td rowspan=1 colspan=1>92</td></tr></table>

There were 2 cquivocal results with the assay. For purposes of calculation, these results wcre considcred as negative. Positive percent agreement: $100 \%$ (52/52) Negative percent agreement: $9 8 . 4 8 \%$ (65/66) Overall agreement: $9 9 . 1 5 \%$ (117/118)

There is I cquivocal result with the assay. For purposes of calculation, these results were considered as negative. Positive percent agreement: $100 \%$ (25/25) Negative percent agrcement: $100 \%$ (67/67) Overall agrcement: $100 \%$ (92/92)

<table><tr><td rowspan=3 colspan=2>SmN=96</td><td></td><td></td><td></td></tr><tr><td rowspan=1 colspan=3></td></tr><tr><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>TotaI</td></tr><tr><td rowspan=3 colspan=1></td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>24</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>27</td></tr><tr><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>69</td><td rowspan=1 colspan=1>69</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>24</td><td rowspan=1 colspan=1>72</td><td rowspan=1 colspan=1>96</td></tr></table>

<table><tr><td rowspan=2 colspan=2>Sm/RNPN= 103</td><td rowspan=1 colspan=3>RAI</td></tr><tr><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=3 colspan=1></td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>32</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>35</td></tr><tr><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>68</td><td rowspan=1 colspan=1>68</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>32</td><td rowspan=1 colspan=1>71</td><td rowspan=1 colspan=1>103</td></tr></table>

There were 5 equivocal results with the assay. For purposes of calculation, these results wcre considered as negative.

Positive percent agreement: $1 0 0 \%$ (24/24) Negative percent agreement: $9 5 . 8 3 \%$ (69172) Overall agrecment: $9 6 . 8 8 \%$ (93/96)

There were 6 borderline results with the assay. For purposes of calculation, these results were considered as negative. Positive percent agreement: $100 \%$ (32/32) Negative percent agreement: $9 5 . 7 7 \%$ (68/71) Overall agreement: $9 7 . 0 9 \%$ (100/103)

<table><tr><td rowspan=2 colspan=2>Scl70N=97</td><td rowspan=1 colspan=3></td></tr><tr><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=3 colspan=1></td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>29</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>29</td></tr><tr><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>68</td><td rowspan=1 colspan=1>68</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>29</td><td rowspan=1 colspan=1>68</td><td rowspan=1 colspan=1>97</td></tr></table>

<table><tr><td rowspan=2 colspan=2>Jo1N=95</td><td rowspan=1 colspan=3>JMANUAL</td></tr><tr><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=2 colspan=1></td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>26</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>26</td></tr><tr><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>69</td><td rowspan=1 colspan=1>69</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>26</td><td rowspan=1 colspan=1>69</td><td rowspan=1 colspan=1>95</td></tr></table>

There is O equivocal result with the assay. Positive percent agreement: $100 \%$ (29/29) Negative percent agreement: $100 \%$ (68/68) Overall agreement: $100 \%$ (97/97)

There is 0 equivocal result with the assay. Positive percent agreement: $1 0 0 \%$ (26/26) Negative percent agreement: $1 0 0 \%$ (69/69) Overall agreement: $100 \%$ (95/95)

<table><tr><td rowspan=2 colspan=2>CentromereN=93</td><td rowspan=1 colspan=3></td></tr><tr><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=3 colspan=1></td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>24</td></tr><tr><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>69</td><td rowspan=1 colspan=1>69</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>73</td><td rowspan=1 colspan=1>93</td></tr></table>

There were 6 equivocal rcsults with the assay. For purpose of calculation, these results were considered as negative.

Positive percent agreement: $100 \%$ (20/20) Negative percent agreement: $9 4 . 5 2 \%$ (69/73) Overall agreement: $9 5 . 7 0 \%$ (89/93)

<table><tr><td rowspan=3 colspan=3>RibosomeN=76</td><td></td><td></td><td></td></tr><tr><td rowspan=1 colspan=3></td></tr><tr><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=2 colspan=2></td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>8</td></tr><tr><td rowspan=1 colspan=1>RISW</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>68</td><td rowspan=1 colspan=1>68</td></tr><tr><td rowspan=1 colspan=2></td><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>68</td><td rowspan=1 colspan=1>76</td></tr></table>

There is 0 cquivocal result with the assay.

Positive percent agreement: $1 0 0 \%$ (8/8) Negative percent agreement: $100 \%$ (68/68) Overall agreement: $100 \%$ (76/76)

Table 12: Summary of performance agreement results   

<table><tr><td rowspan=1 colspan=1>AntigenicSpecificity</td><td rowspan=1 colspan=1>Samplenumber</td><td rowspan=1 colspan=1>Positivepercentagreement</td><td rowspan=1 colspan=1>Negativepercentagreement</td><td rowspan=1 colspan=1>Overallagreement</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>proportion</td><td rowspan=1 colspan=1>proportion</td><td rowspan=1 colspan=1>proportion</td></tr><tr><td rowspan=1 colspan=1>dsDNA</td><td rowspan=1 colspan=1>112</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>SSA 60 kDa</td><td rowspan=1 colspan=1>110</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>SSA 52 kDa</td><td rowspan=1 colspan=1>118</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>98.48%</td><td rowspan=1 colspan=1>98.48%</td></tr><tr><td rowspan=1 colspan=1>SSB</td><td rowspan=1 colspan=1>92</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>Sm</td><td rowspan=1 colspan=1>96</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>95.83%</td><td rowspan=1 colspan=1>95.83%</td></tr><tr><td rowspan=1 colspan=1>Sm/RNP</td><td rowspan=1 colspan=1>13</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>95.77%</td><td rowspan=1 colspan=1>95.77%</td></tr><tr><td rowspan=1 colspan=1>Scl70</td><td rowspan=1 colspan=1>97</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>Jo1</td><td rowspan=1 colspan=1>95</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>Centromere</td><td rowspan=1 colspan=1>93</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>94.52%</td><td rowspan=1 colspan=1>94.52%</td></tr><tr><td rowspan=1 colspan=1>Ribosome</td><td rowspan=1 colspan=1>76</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>100%</td></tr></table>

In addition to the analysis above, the 95% one-sided lower confidence limit in percent of proportion agreement (95% LCL (%) was calculated using the Exact Binomial Test for proportions to determine how low this proportion could be with a $9 5 \%$ confidence.

Table 13: Summary of performance agreements results - 95 % LCL (%)   

<table><tr><td rowspan=1 colspan=1>AntigenicSpecificity</td><td rowspan=1 colspan=4>Positive percent agreement</td><td rowspan=1 colspan=4>Negative percent agreement</td><td rowspan=1 colspan=4>Overall percent agreement</td></tr><tr><td rowspan=1 colspan=1>S</td><td rowspan=1 colspan=1>N$</td><td rowspan=1 colspan=1>R</td><td rowspan=1 colspan=1>P(%)</td><td rowspan=1 colspan=1>95% LCL(%)</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>R</td><td rowspan=1 colspan=1>P(%)</td><td rowspan=1 colspan=1>95% LCL (%)</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>R</td><td rowspan=1 colspan=1>P(%)</td><td rowspan=1 colspan=1>95% LCL (%)</td></tr><tr><td rowspan=1 colspan=1>dsDNA</td><td rowspan=1 colspan=1>43</td><td rowspan=1 colspan=1>43</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>93.27</td><td rowspan=1 colspan=1>69</td><td rowspan=1 colspan=1>69</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>95.75</td><td rowspan=1 colspan=1>112</td><td rowspan=1 colspan=1>112</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>97.36</td></tr><tr><td rowspan=1 colspan=1>SSA 60 kDa</td><td rowspan=1 colspan=1>42</td><td rowspan=1 colspan=1>42</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>93.12</td><td rowspan=1 colspan=1>68</td><td rowspan=1 colspan=1>68</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>95.69</td><td rowspan=1 colspan=1>110</td><td rowspan=1 colspan=1>110</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>97.31</td></tr><tr><td rowspan=1 colspan=1>SSA 52 kDa</td><td rowspan=1 colspan=1>52</td><td rowspan=1 colspan=1>52</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>94.40</td><td rowspan=1 colspan=1>66</td><td rowspan=1 colspan=1>65</td><td rowspan=1 colspan=1>98.48</td><td rowspan=1 colspan=1>93.01</td><td rowspan=1 colspan=1>118</td><td rowspan=1 colspan=1>117</td><td rowspan=1 colspan=1>99.15</td><td rowspan=1 colspan=1>96.04</td></tr><tr><td rowspan=1 colspan=1>SSB</td><td rowspan=1 colspan=1>25</td><td rowspan=1 colspan=1>25</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>88.71</td><td rowspan=1 colspan=1>67</td><td rowspan=1 colspan=1>67</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>95.63</td><td rowspan=1 colspan=1>92</td><td rowspan=1 colspan=1>92</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>96.80</td></tr><tr><td rowspan=1 colspan=1>$m</td><td rowspan=1 colspan=1>24</td><td rowspan=1 colspan=1>24</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>88.27</td><td rowspan=1 colspan=1>72</td><td rowspan=1 colspan=1>69</td><td rowspan=1 colspan=1>95.83</td><td rowspan=1 colspan=1>89.58</td><td rowspan=1 colspan=1>96</td><td rowspan=1 colspan=1>93</td><td rowspan=1 colspan=1>96.88</td><td rowspan=1 colspan=1>92.12</td></tr><tr><td rowspan=1 colspan=1>Sm/RNP</td><td rowspan=1 colspan=1>32</td><td rowspan=1 colspan=1>32</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>91.06</td><td rowspan=1 colspan=1>71</td><td rowspan=1 colspan=1>68</td><td rowspan=1 colspan=1>95.77</td><td rowspan=1 colspan=1>89.44</td><td rowspan=1 colspan=1>103</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>97.09</td><td rowspan=1 colspan=1>92.64</td></tr><tr><td rowspan=1 colspan=1>Scl70</td><td rowspan=1 colspan=1>29</td><td rowspan=1 colspan=1>29</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>90.19</td><td rowspan=1 colspan=1>68</td><td rowspan=1 colspan=1>68</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>95.69</td><td rowspan=1 colspan=1>97</td><td rowspan=1 colspan=1>97</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>96.96</td></tr><tr><td rowspan=1 colspan=1>Jo1</td><td rowspan=1 colspan=1>26</td><td rowspan=1 colspan=1>26</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>89.12</td><td rowspan=1 colspan=1>69</td><td rowspan=1 colspan=1>69</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>95.75</td><td rowspan=1 colspan=1>95</td><td rowspan=1 colspan=1>95</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>96.90</td></tr><tr><td rowspan=1 colspan=1>Centromere</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>86.09</td><td rowspan=1 colspan=1>73</td><td rowspan=1 colspan=1>69</td><td rowspan=1 colspan=1>94.52</td><td rowspan=1 colspan=1>87.90</td><td rowspan=1 colspan=1>93</td><td rowspan=1 colspan=1>89</td><td rowspan=1 colspan=1>95.70</td><td rowspan=1 colspan=1>90.43</td></tr><tr><td rowspan=1 colspan=1>Ribosome</td><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>68.77</td><td rowspan=1 colspan=1>68</td><td rowspan=1 colspan=1>68</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>95.69</td><td rowspan=1 colspan=1>76</td><td rowspan=1 colspan=1>76</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>96.13</td></tr></table>

$\Nu _ { 1 } = \Nu _ { 0 }$ of positives R1 = No. of positive agreements; P1 = Rj/N, N2 = No. of negatives; R2 = No. of negative agreemerits; P2 = R2/N2 $\Nu = \Nu _ { 1 } + \Nu _ { 2 }$ . $\mathbb { R } = \mathbb { R } _ { 1 } + \mathbb { R } _ { 2 }$ ., ${ \bf P } = { \bf R } / { \bf N }$

All prev valuati resul indica  anal uta (wi CARI) assay preparation steps are considered substantially equivalents.

# . Conclusions

In conclusion, all supporting data demonstrate that the FIDIS™M CONNECTIVE 10\* system can be considered substantially equivalent to the predicate device.

# DEC 1 9 2007

Biomedical Diagnostics S.A. (BMD)   
c/o Ms. Christelle Courivaud   
Regulatory Affairs Manager   
Actipole 25,   
4-6 Bld de Beaubourg   
77435 Marne La Vallée cedex 2   
France

Re: k071210 Trade/Device Name: FIDISTM CONNECTIVE $1 0 ^ { * }$ Assay Regulation Number: 21 CFR 866.5100 Regulation Name: Antinuclear antibody immunological test system Regulatory Class: Class II Product Code: LLL, LKS, LKO, LKP, LSW, LIM, MQA Dated: December 5, 2007 Received: December 7, 2007

Dear Ms. Courivaud:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

I yur devic i classedee above) into either class II(Specal Controls) or classII MA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies.You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (1 R Part 20).This letter wil allow ou to

Page 2 -

begin marketing your device as described in your Section $5 1 0 ( \mathrm { k } )$ premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific information about the application of labeling requirements to your device, or questions on the promotion and advertising of your device, please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (240) 276-0450. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding postmarket surveillance, please contact CDRH's Office of Surveillance and Biometric's (OSB's) Division of Postmarket Surveillance at 240-276-3474. For questions regarding the reporting of device adverse events (Medical Device Reporting (MDR)), please contact the Division of Surveillance Systems at 240-276-3464. You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely yours,

![](images/62a039bf9e258811fb62002c5275c5585fe23628791b99c3c676d78e1b70d1ea.jpg)

Robert L. Becker, Jr., M.D., Ph.D.   
Director   
Division of Immunology and Hematology Devices   
Office of In Vitro Diagnostic Device Evaluation and Safety Center for Devices and Radiological Health

# Indication for Use

510(k) Number (if known): K071210

Device Name: FIDIS™M CONNECTIVE 10\*

# Indication For Use:

The FIDIS™™ CONNECTIVE 10\* kit is a semi-quantitative homogeneous fluorescent-based microparticles immunoassay using flow cytometry. The test system is used to simultaneously detect the presence of 10 autoantibody specificities: double stranded DNA (dsDNA), SSA (60 kDa and 52 kDa), SSB, Sm, Sm/RNP, Scl70, Jo1, ribosome and centromere.

(\*Antibodies to dsDNA, Sm, Sm/RNP, SSA, SB, Scl-70, Jo-1, ribosome and centromere can be reported using this assay).

# Clinical utility:

The results of the FIDIS™M CONNECTIVE 10\* are to be used in conjunction with the clinical findings and the other laboratory tests to aid in the diagnosis of connective diseases (systemic lupus erythematosus (SLE), Sjogren's syndrome, mixed connective tissue disease (MCTD), scleroderma, dermatomyositis and CREST syndrome).

FIDIS™ CONNECTIVE 10\* kit uses serum only, and is to be run on the FIDIS™M Instrument and MLX-BOOSTER™M Software.

FIDIS™M CONNECTIVE 10\* kit may be used with the CARIS™M system (diluting and dispensing device).

This test is for in vitro diagnostic use.

# Concurrence of CDRH, Office of In Vitro Diagnostic Device Evaluation and Safety (OIVD)

Division Sign-Off   
Office of In Vitro Diagnostic Device   
Evaluation and Safety

Section D- Paao 2